Access Restriction

Author Shiell, Kerrie
Source CiteSeerX
Content type Text
File Format PDF
Subject Domain (in DDC) Computer science, information & general works ♦ Data processing & computer science
Subject Keyword Chronic Imatinib Use ♦ First Line Treatment ♦ Targeted Kinase ♦ Lymphoma Group ♦ Chronic Myeloid Leukaemia ♦ Australasian Leukaemia ♦ Reproductive System ♦ Potential Neurotoxic Effect ♦ Possible Neuropsychological Sequela ♦ Animal Study ♦ Haematology-oncology Practice ♦ Deleterious Consequence ♦ Protein Kinase ♦ Survival Advantage ♦ Synaptic Efficacy ♦ Long-term Basis ♦ Potential Toxic Effect ♦ Impaired Learning ♦ Target Kinase Inhibitor ♦ Safety Sub-study ♦ Blastic Phase ♦ Subtle Effect
Abstract Imatinib was successfully introduced into haematology-oncology practice in 2001 and rapidly endorsed as a first line treatment for chronic myeloid leukaemia (CML) in the chronic, accelerated, and blastic phases. The survival advantage demonstrated by this target kinase inhibitor has meant that patients are now treated with this agent on a long-term basis. There is a growing literature on the potential toxic effects of chronic imatinib use (Fruttiger et al., 1999; Grove et al., 2004). A safety sub-study undertaken by the Australasian Leukaemia and Lymphoma Group (ALLG) identified a range of subtle effects consistent with the inhibition of targeted kinases in the immunological, respiratory, endocrine, and reproductive systems (Seymour et al., 2004). To date, there has been no attempt to elucidate possible neuropsychological sequelae of chronic imatinib use. However concerns exist about the potential neurotoxic effects of this agent, given that the inhibition of protein kinase in animal studies has been associated with a range of deleterious consequences, such as impaired learning and memory, and reduced synaptic efficacy (Grove et al., 2004; Moresco et al., 2003).
Educational Role Student ♦ Teacher
Age Range above 22 year
Educational Use Research
Education Level UG and PG ♦ Career/Technical Study
Publisher Date 2009-01-01